Berzosertib for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 May 2018: Trial registered, NCT03517969
  2. 29 May 2019: Trial started, NCT03517969

The trials

NCT03517969: M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

State
Under way
Phase
Phase 2
People
73 taking part
Started
29 May 2019
Primary completion
10 Aug 2021
Arms
Arm B (carboplatin, berzosertib)
Results
Posted on the registry
  1. 8 May 2018: Trial registered
  2. 29 May 2019: Trial started
  3. 8 May 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.